Non Small Cell Lung CancerPhase 4PROMETHEENCT06646471
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
A Phase 4 study testing Bio-bank repository, Quality of Life (QoL) and G-Code in people with Non Small Cell Lung Cancer and Lung Cancer, run by GFPC Investigation at 41 sites in France.
Trial summary
The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer, Lung Cancer
- What is being tested?
- Bio-bank repository, Quality of Life (QoL) and G-Code
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 41 sitesFrance
- Study dates
- 26 Sep 2024to 31 Aug 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Patient ≥70 years
- Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
- Patient naïve to systemic anticancer treatment for bronchial neoplasia
- Patient covered by social security
- Patient eligible for systemic treatment
- Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.
Show all 9Show fewer
- Patient able to understand the protocol
- Patient not opposed to the collection of data concerning him/her
- Signature of study consent form.
Who cannot join
- Patients under guardians or curators
- Patient not under the care of the investigating center and not monitored by the investigating center
- Patient already treated with systemic therapy for NSCLC
Trial locations and contacts
41 sites in 1 country. Contact the study team or a site near you to ask about taking part.
41 sites in 1 country
France41 sites, 41 recruiting
- Recruiting
CH du Pays d Aix
Aix-en-Provence, 13616
Stéphanie MARTINEZ, smartinez@ch-aix.fr
- Recruiting
Hôpital Henri Duffaut
Avignon, 84000
Nicolas CLOAREC, clarec.nicolas@ch-avignon.fr
- Recruiting
Institut du Cancer d'Avignon
Avignon, 84918
Magali RAVOIRE, m.ravoire@isc84.org
- Not yet recruiting
CH Bastia
Bastia, 20600
Pascal THOMAS, pascal.thomas@ch-bastia.fr
- Recruiting
Oncologie Thoracique Hôpital Morvan
Brest, 29200
Renaud DESCOURT, renaud.descourt@chu-brest.fr
- Not yet recruiting
Pneumologie Centre François Baclesse
Caen, 14000
Hubert CURCIO, h.curcio@baclesse.unicncer.fr
- Recruiting
CH Métropole-Savoie
Chambéry, 73000
Julian PINSOLLE, julian.pinsolle@ch-metropole-savoie.fr
- Recruiting
Centre Hospitalier du Cotentin
Cherbourg, 50102
Laure KALUZINSKI, l.kaluzinski@ch-cotentin.fr
- Not yet recruiting
CHU Hôpital Montpied
Clermont-Ferrand, 63000
Patrick MERLE, pmerle@chu-clermontferrand.fr
- Recruiting
Pneumologie Hospices Civils de Colmar
Colmar, 68024
Lionel MOREAU, lionel.moreau@ch-colmar.fr
- Recruiting
Pneumologie CHI Creteil
Créteil, 94010
Isabelle MONNET, isabelle.monnet@chicreteil.fr
- Recruiting
CH Elbeuf
Elbeuf, 76503
Pierre Alexandre HAUSS, Pierre-Alexandre.Hauss@chi-elbeuf-louviers.fr
- Not yet recruiting
Polyclinique de Blois
La Chaussée-Saint-Victor, 41260
Philippe LAPLAIGE, dr.laplaige@wanadoo.fr
- Recruiting
CHD Les Oudairies
La Roche-sur-Yon, 85000
Acya BIZIEUX, acya.bizieux@ght85.fr
- Recruiting
CH La Rochelle
La Rochelle, 17000
Marion LAFARGE, marion.lafarge@ght-atlantique17.fr
- Recruiting
Hôpital A. Mignot
Le Chesnay, 78157
Cécile DUJON, Cdujon@ght78sud.fr
- Recruiting
Hôpital Robert Boulin
Libourne, 33505
Samir ABDICHE, menouar-samir.abdiche@ch-libourne.fr
- Recruiting
CHU Dupuytren
Limoges, 87042
Yannick SIMONNEAU, yannick.simonneau@chu-limoges.fr
- Recruiting
Hôpital de la Vallée - Service Pneumologie
Longjumeau, 91160
Alain BAKEBE, a.bakebe@gh-nord-essonne.fr
- Recruiting
Centre Léon Bérard
Lyon, 69373
Chantal DECROISETTE, chantal.decroisette@lyon.unicancer.fr
- Recruiting
Hôpital Européen de Marseille
Marseille, 13003
Jacques LE TREUT, j.letreut@hopital-europeen.fr
- Recruiting
Oncologie Thoracique Hôpital Nord
Marseille, 13915
Laurent GREILLIER, laurent.greillier@ap-hm.fr
- Recruiting
GHEF Site de Meaux
Meaux, 77100
Chrystèle LOCHER, chlocher@ghef.fr
- Recruiting
Centre d Oncologie de Gentilly
Nancy, 54000
Laurene GAVOILLE, L.gavoille@oncog.fr
- Recruiting
Pneumologie CHR
Orléans, 45067
Hugues MOREL, hugues.morel@chr-orleans.fr
- Not yet recruiting
Pneumologie Hôpital Cochin
Paris, 75014
Marie WISLEZ, marie.wislez@aphp.fr
- Not yet recruiting
Pneumologie Hôpital Tenon
Paris, 75970
Constance METEYE, constance.meteye@aphp.fr
- Not yet recruiting
Cantre Catalan d Oncologie
Perpignan, 66000
Sabine VIEILLOT, sabinevieillot@gmail.com
- Recruiting
CH Annecy Genevois
Pringy, 74374
Emilie PLUQUET, epluquet@ch-annecygenevois.fr
- Recruiting
Pneumologie CHI Quimper
Quimper, 29000
Romain CORRE, romain.corre@ch-cornouaille.fr
- Recruiting
CHU Hôpital Ponchailloux
Rennes, 35033
Charles RICORDEL, charles.ricordel@chu-rennes.fr
- Not yet recruiting
Pneumologie Hôpital Charles Nicolle
Rouen, 76031
Florian GUISIER, florian.guisier@chu-rouen.fr
- Recruiting
Pneumologie CHU Felix Guyon
Saint-Denis, 97400
Diane MOREAU, diane.moreau@chu-reunion.fr
- Recruiting
Pneumologie CHU St Etienne
Saint-Etienne, 42270
Sophie BAYLE-BLEUEZ, sophie.bayle@chu-st-etienne.fr
- Recruiting
Clinique Mutualiste
Saint-Nazaire, 44600
Thierry CHATELLIER, thierry.chatellier@hospigrandouest.fr
- Recruiting
CHU de la Réunion
Saint-Pierre, 97410
Eric HUCHOT, eric.huchot@chu-reunion.fr
- Recruiting
CLCC Paul Strauss
Strasbourg, 67000
Roland SCHOTT, r.schott@icans.eu
- Recruiting
Hôpital d'Instruction des Armées Saint-Anne
Toulon, 83041
Olivier BYLICKI, bylicki.olivier@yahoo.fr
- Recruiting
CHITS Toulon Sainte Musse
Toulon, 83056
Clarisse AUDIGIER VALETTE, clarisse.audigier-valette@ch-toulon.fr
- Recruiting
Oncologie CHBA
Vannes, 56000
Gonzague DE CHABOT, gonzague.dechabot@ch-bretagne-atlantique.fr
- Recruiting
Hôpital Nord OUest
Villefranche-sur-Saône, 69655
Lionel FALCHERO, LFalchero@lhopitalnordouest.fr
About this study
Official title: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly
The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to:
- characterize participants in terms of geriatrics, biology and carcinology
- describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life.
Read more
At the same time, exploratory sub-cohorts will be identified including participants treated uniformly with the same molecule, and/or the same innovative strategy.
Participants will be followed in accordance with investigator's usual clinical practice at the corresponding site. They will be asked to:
- visit the clinic as per physician's request for checkups and tests for assessing general condition and clinical efficacy and tolerance of current treatment.
- perform the necessary regular para-clinical examinations (lab testing, imaging, re-biopsy).
- provide blood samples for bio-bank repository
- perform assessments specific to older adults
- answer three quality of life questionnaires
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer
- Being tested
- Bio-bank repository, Quality of Life (QoL), G-Code
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bio-bank repositoryGenetic
Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
Quality of Life (QoL)Other
Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:
- stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.
- operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.
- radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months.
G-CodeProcedure or surgery
G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
| Study group | Role | What they receive |
|---|---|---|
| Real world cohort of NSCLC older adults patients | Other | Cohort of patients ≥70 years of age with NSCLC treated in first line therapy for thoracic tumors according to ESMO-referenced therapeutic standards or according to an innovative molecule and/or strategy.
An optional biobank based on blood samples taken during the screening phase prior to the first administration of systemic treatment will be collected. Sampling of tumoral materials will be collected prior to study participation and send for central reading.
Patients will be asked to come at the hospital for their regular visits as per site current practice and to complete three quality of life questionnaires (EORTC QLQ-F17; QLQ-LC13; QLQ-ELD14). Receives: Genetic: Bio-bank repository; Other: Quality of Life (QoL); Procedure: G-Code |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression Free Survival (PFS)
The Progression Free Survival is defined as the time between treatment start date and event date defined by the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 progression or death for any cause, whichever comes first.
Disease progression will be evaluated according to (RECIST) 1.1 assessed locally. Frequency of this assessment is let to the investigator \'s discretion and local practices.
The participants will be followed until disease progression or death for any cause. Patients without an event at the time of analysis will be censored at the date of their last tumor assessment.
Measured: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years
Secondary outcomes (16)
Objective Response Rate (ORR)
The objective response rate (ORR) is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria based on tumoral assessment performed by thorax-abdominal-pelvic and brain CT scans. The frequency of the tumor assessments will follow the site practices.
Measured: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years
Overall Survival (OS)
Overall survival (OS) is calculated as the time between the date of treatment initiation and date of death, and censored at date of last news for patients alive at the end of the study.
Measured: From the treatment start date up to the date of death for a 2-year-period maximum
Duration of Response (DOR)
The duration of response is defined as the time between the date of the first response assessed by RECIST 1.1 to the date of progression or death for any cause, whichever comes first, and censored at the date of last tumor evaluation for patients still responding to treatment at the end of the study (after 2 years).
Measured: From the date of the first response to the date of progression or death, whichever comes first, or for a 2-year-period maximum
Time to Response (TTR)
Time to response is measured from the date of treatment initiation to the date of first response as defined by RECIST 1.1.
Measured: From the start date of treatment up to the date of first response or for a 2-year-period maximum
Treatment Duration
The duration of treatment is defined as the time between the treatment start date and the date of definitive cessation of treatment, whatever the cause.
Measured: From the treatment start date and the treatment stop date whatever the cause up to a 2-year-period maximum.
Safety events
All adverse events experienced by the participants, whatever the grades of toxicity, will be collected according to CTCAE v4.0 (common terminology criteria for adverse events).
Measured: From the enrollment up to the participants study end date or for a 2-year-period maximum
Treatments description
The treatments for NSCLC will be described including the adaptations: discontinuations, treatment interruptions, dose adaptations. The reasons for the changes will be recorded.
Measured: From the start date of the NSCLC treatment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized consultations
The specialized geriatric consultations carried out to correct frailties will be collected during the study participation including psychological and/or dietetic consultations.
Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized exercises
The specialized geriatric exercises carried out to correct frailties will be collected during the study participation including prescription of adapted physical activity and/or cognitive stimulation exercises.
Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized help at home
The specialized geriatric interventions at home carried out to correct frailties will be collected during the study participation including home visits by a nurse or home help.
Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized medications
The specialized geriatric medications carried out to correct frailties will be collected during the study participation.
Measured: From the enrollment up to the participant study end date or for a 2-year-period maximum
European Organisation for Research and Treatment of Cancer Core Function Questionnaire (QLQ-F17)
The QLQ-F17 is a validated cancer-specific questionnaire specific to cancer. It includes 17 items to assess 6 QoL scales: 1 global health scale and 5 functional scales (physical, role,emotional, cognitive, social). This is a shortened version of the QLQ-C30, containing only the functional and overall quality of life sections. This questionnaire was developed by the EORTC in order to optimize the collection of quality-of-life data, and to avoid overloading the patient with a lengthy questionnaire.
Symptoms will be assessed via modules. A score is generated for each dimension and standardized on a scale from 0 to 100, so that a high score reflects a high overall health status, a high functional level and a high symptomatic level. According to EORTC recommendations, the score can be calculated if at least 50% of the items in the corresponding dimension have been completed. Otherwise, the score will be considered missing.
Measured: At enrolment, at 12 weeks, at 6 months and at 12 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-ELDerly 14 (QLQ-ELD14)
The QLQ-ELD14 questionnaire is specific to elderly cancer patients. It contains 14 items measuring 7 dimensions of quality of life : two functional dimensions (maintaining a positive positive vision/motivation, family support) and 5 symptomatic dimensions (mobility, worries about others, worries about the future, disease burden, joint problems).
All of the scales and single-item range in score from 0-100. A score is generated for each dimension, so that a high score reflects a high functional level (for the scales concerned), and a high symptomatic level (for the scales concerned).
Measured: At enrolment, at 12 weeks, at 6 months and at 12 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
The QLQ-LC13 is a lung cancer-specific questionnaire containing 13 items to assess symptoms specific to lung cancer and its treatment: dyspnea, cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm or shoulder pain or shoulder pain, pain in other parts, anti-inflammatory drugs, drugs for pain. A score is generated per dimension so that a high score reflects a high symptomatic level.
All of the scales and single-item range in score from 0-100. A high scale score represents a higher response level.
Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status represents a high quality of life, but a high score for symptom scale/item represents a high level of symptomatology/problems.
Measured: At enrolment, at 12 weeks, at 6 months and at 12 months
Geriatric characteristics G8 score
The following geriatric characteristics will be collected is available in the participant medical file: G8 score.
The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
Measured: At enrollment and at disease progression for a maximum of 2-year-period.
Geriatric characteristics Geriatric Core DatasEt (G-CODE)
The following geriatric characteristics will be collected is available in the participant medical file: Geriatric Core DatasEt (G-CODE). G-CODE is a core set of geriatric data. It has ten tools/items and a median completion time of 9 min. It includes Katz autonomy scale (ADL), Instrumental Activities of Daily Living (IADL), Charlson score, mini Geriatric Depression Sale (mini-GDS), short cognitive impairment screening exam (mini COG), falls history, Timed Get Up and Go test, social environment.
The G-CODE allows for a minimal geriatric description of the older cancer population and standardisation of geriatric data, enabling comparison across trials.
Measured: At enrollment and at disease progression for a maximum of 2-year-period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2024
- Study start26 Sep 2024
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GFPC Investigation
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laurent GREILLIER, Professor, Study chair, Groupe Français de Pneumo-Cancérologie (GFPC)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06646471
- Sponsor's protocol ID
- GFPC 05-2023
- Acronym
- PROMETHEE
- Status last verified
- Apr 2026
- First submitted
- 27 Sep 2024
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly
- ClinicalTrials.gov ID
- NCT06646471
- Acronym / sponsor ID
- PROMETHEE / GFPC 05-2023
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- GFPC InvestigationUniversity, hospital or other
- Study start
- 26 Sep 2024 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Aug 2028 (estimated)
- First posted
- 17 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to:
- characterize participants in terms of geriatrics, biology and carcinology
- describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life.
At the same time, exploratory sub-cohorts will be identified including participants treated uniformly with the same molecule, and/or the same innovative strategy.
Participants will be followed in accordance with investigator's usual clinical practice at the corresponding site. They will be asked to:
- visit the clinic as per physician's request for checkups and tests for assessing general condition and clinical efficacy and tolerance of current treatment.
- perform the necessary regular para-clinical examinations (lab testing, imaging, re-biopsy).
- provide blood samples for bio-bank repository
- perform assessments specific to older adults
- answer three quality of life questionnaires
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Real world cohort of NSCLC older adults patients | Other | Genetic: Bio-bank repository, Other: Quality of Life (QoL), Procedure: G-CodeCohort of patients ≥70 years of age with NSCLC treated in first line therapy for thoracic tumors according to ESMO-referenced therapeutic standards or according to an innovative molecule and/or strategy. An optional biobank based on blood samples taken during the screening phase prior to the first administration of systemic treatment will be collected. Sampling of tumoral materials will be collected prior to study participation and send for central reading. Patients will be asked to come at the hospital for their regular visits as per site current practice and to complete three quality of life questionnaires (EORTC QLQ-F17; QLQ-LC13; QLQ-ELD14). |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (9 listed)
- Patient ≥70 years
- Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
- Patient naïve to systemic anticancer treatment for bronchial neoplasia
- Patient covered by social security
- Patient eligible for systemic treatment
Key exclusion criteria (3 listed)
- Patients under guardians or curators
- Patient not under the care of the investigating center and not monitored by the investigating center
- Patient already treated with systemic therapy for NSCLC
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bio-bank repositoryBlood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years | Genetic | Real world cohort of NSCLC older adults patients |
| Quality of Life (QoL)Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14: * stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression. * operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months. * radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months. | Other | Real world cohort of NSCLC older adults patients |
| G-CodeG-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment. | Procedure or surgery | Real world cohort of NSCLC older adults patients |
Primary outcome
Progression Free Survival (PFS)
Time frame: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years
The Progression Free Survival is defined as the time between treatment start date and event date defined by the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 progression or death for any cause, whichever comes first. Disease progression will be evaluated according to (RECIST) 1.1 assessed locally. Frequency of this assessment is let to the investigator \'s discretion and local practices. The participants will be followed until disease progression or death for any cause. Patients without an event at the time of analysis will be censored at the date of their last tumor assessment.
16 secondary outcomes
Objective Response Rate (ORR)
Time frame: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years
Overall Survival (OS)
Time frame: From the treatment start date up to the date of death for a 2-year-period maximum
Duration of Response (DOR)
Time frame: From the date of the first response to the date of progression or death, whichever comes first, or for a 2-year-period maximum
Time to Response (TTR)
Time frame: From the start date of treatment up to the date of first response or for a 2-year-period maximum
Treatment Duration
Time frame: From the treatment start date and the treatment stop date whatever the cause up to a 2-year-period maximum.
Safety events
Time frame: From the enrollment up to the participants study end date or for a 2-year-period maximum
Treatments description
Time frame: From the start date of the NSCLC treatment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized consultations
Time frame: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized exercises
Time frame: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized help at home
Time frame: From the enrollment up to the participant study end date or for a 2-year-period maximum
Geriatric interventions: specialized medications
Time frame: From the enrollment up to the participant study end date or for a 2-year-period maximum
European Organisation for Research and Treatment of Cancer Core Function Questionnaire (QLQ-F17)
Time frame: At enrolment, at 12 weeks, at 6 months and at 12 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-ELDerly 14 (QLQ-ELD14)
Time frame: At enrolment, at 12 weeks, at 6 months and at 12 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
Time frame: At enrolment, at 12 weeks, at 6 months and at 12 months
Geriatric characteristics G8 score
Time frame: At enrollment and at disease progression for a maximum of 2-year-period.
Geriatric characteristics Geriatric Core DatasEt (G-CODE)
Time frame: At enrollment and at disease progression for a maximum of 2-year-period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
RecruitingObservational study
Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
HER2-mutant Advanced Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 2
Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer
Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laurent GREILLIER, Professor study chair
Groupe Français de Pneumo-Cancérologie (GFPC)
41 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Bio-bank repository, Quality of Life (QoL) and G-Code in people with Non Small Cell Lung Cancer and Lung Cancer, run by GFPC Investigation at 41 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Romain CORRE, Medical Doctor (+330298526404, romain.corre@ch-cornouaille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression Free Survival (PFS) (time frame: From the date of first dose of treatment received until the date of the first documented disease progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 or to death from any cause, whichever comes first, assessed up to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.